Acceleron Pharma will present the results of a Phase 1 clinical study of ACE-083, its lead investigational therapeutic for patients with facioscapulohumeral muscular dystrophy, at the 14th International Congress on Neuromuscular Disease (ICNMD 2016) taking place in Toronto, Canada, on July 5–9. According to a press release, the poster, “ACE-083, A Locally-Acting…
News
MaestroSoft, a fundraising solutions company, announced that its Text2Bid technology was used to support the Muscular Dystrophy’s Association of Southern Wisconsin’s Annual Black-N-Blue Ball, a money-raising event for muscular dystrophy (MD). Text2Bid allows guests at auctions to be notified by text message on the status of their bidding, making…
Parent Project Muscular Dystrophy (PPMD), a non-profit organization fighting to find a cure for Duchenne muscular dystrophy (DMD), recently announced that Marathon Pharmaceuticals will support the organization’s ongoing Certified Duchenne Care Center (CDCC) Program with a new grant. “We recognize that the Duchenne community needs the kind of…
News
Ability of Duchenne MD Children to Use Stairs Should Be Evaluated Every 9-12 Months, Study Suggests
The ability to climb up stairs should be assessed at intervals of nine months or longer and the ability to go down should be assessed annually in Duchenne muscular dystrophy (DMD) according to a new study.
The FSH Society, a non-profit organization led by facioscapulohumeral muscular dystrophy (FSHD) patients in support of research and education, joined other FSH groups worldwide in hosting the first World FSHD Day on June 20. The day was developed with FSHD Champions, an international alliance of organizations advocating for awareness…
News
Catabasis to Present Data from MoveDMD Trial in Duchenne Patients at PPMD 2016 Annual Conference
Catabasis’ chief medical officer, Dr. Joanne Donovan, will present results from the first phase of the two-part MoveDMD Trial, exploring the company’s investigational drug edasalonexent (CAT-1004) in patients with Duchenne muscular dystrophy (DMD). The presentation will take place at the 2016 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference, set…
Santhera Pharmaceuticals reports that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for its drug Raxone (idebenone; U.S. brand name, Catena) as a treatment for Duchenne muscular dystrophy (DMD) in patients with respiratory function decline and who are not under glucocorticoid therapy. The EMA validation confirms…
Raul Carranza was born in Chula Vista 27 years ago. The recent graduate in political science from the University of California San Diego, and future law student, is one of the university’s most heralded students. Diagnosed with muscular dystrophy (MD) at the age of two, and by his third birthday…
New research suggests that heart arrhythmia in myotonic dystrophy (DM) patients is caused by mutant RNA in the heart’s sodium channel. The study, which adds to the understanding of this symptom, was titled “Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy,” and published in …
CureDuchenne, a nonprofit group working to advance research and improve care for people with Duchenne muscular dystrophy (DMD), is partnering with Catabasis Pharmaceuticals to host a webinar discussing promising results from the first part of two-part MoveDMD clinical trial. The webinar is set for Wednesday, June 22, at 1 p.m. ET…
Recent Posts
- When school is out, my sons with DMD get into their summer groove
- Upsher-Smith launches new DMD support websites for Kymbee treatment
- Exploring other mobility devices when a walker is no longer sufficient
- Collaboration aims to improve design of FSHD clinical trials
- I won’t apologize for having 3 children with Duchenne MD